Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"IMV","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"IMV","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV to Showcase its DPX\u00ae Delivery Technology in Two Presentations at the AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV Inc. Presents Clinical Benefit of MVP-S in Combination with Pembrolizumab in Bladder Cancer at the AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV\u2019s Lead Compound to Be Showcased in Two Presentations at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Immunovaccine Technologies","sponsor":"Biovaxys","pharmaFlowCategory":"D","amount":"$25.7 million","upfrontCash":"$25.7 million","newsHeadline":"BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r\/r DLBCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for Maveropepimut-S

    Menu

    Maveropepimut-S

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Immunovaccine Technologies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

              Details:

              The acquisition supplements BioVaxys' existing cancer vaccine portfolio with the addition of DPX-Survivac (maveropepimut-S), a DPX™-formulated cancer vaccine that delivers antigenic peptides from survivin, a cancer antigen commonly overexpressed in advanced cancers.

              Lead Product(s): Maveropepimut-S,Pembrolizumab,Cyclophosphamide

              Therapeutic Area: Oncology Product Name: DPX-Survivac

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Biovaxys

              Deal Size: $25.7 million Upfront Cash: $25.7 million

              Deal Type: Acquisition February 12, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IMV

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial

              Details:

              IMV’s lead candidate, DPX-Survivac (maveropepimut-S), delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers.

              Lead Product(s): Maveropepimut-S,Pembrolizumab,Cyclophosphamide

              Therapeutic Area: Oncology Product Name: DPX-Survivac

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IMV

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S

              Details:

              IMV’s lead candidate, DPX-Survivac (maveropepimut-S), delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers.

              Lead Product(s): Maveropepimut-S,Pembrolizumab

              Therapeutic Area: Oncology Product Name: DPX-Survivac

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 08, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IMV

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

              Details:

              DPX-Survivac (maveropepimut-S) is a novel T cell immunotherapy that uses the DPX platform to elicit strong and sustained survivin-specific T cell responses against tumor cells.

              Lead Product(s): Maveropepimut-S,Pembrolizumab,Cyclophosphamide

              Therapeutic Area: Oncology Product Name: DPX-Survivac

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: H.C. Wainwright & Co.

              Deal Size: $9.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering December 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IMV

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

              Details:

              DPX-Survivac (maveropepimut-S) is a novel T cell immunotherapy that uses the DPX platform to elicit strong and sustained survivin-specific T cell responses against tumor cells.

              Lead Product(s): Maveropepimut-S,Pembrolizumab,Cyclophosphamide

              Therapeutic Area: Oncology Product Name: DPX-Survivac

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: H.C. Wainwright & Co.

              Deal Size: $9.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering December 16, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IMV

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL

              Details:

              IMV’s lead candidate, DPX-Survivac (maveropepimut-S, MVP-S), delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers.

              Lead Product(s): Maveropepimut-S,Pembrolizumab

              Therapeutic Area: Oncology Product Name: DPX-Survivac

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 15, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IMV

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IMV’s Lead Compound to Be Showcased in Two Presentations at the 2022 ASCO Annual Meeting

              Details:

              Maveropepimut-S (DPX-Survivac) Generating Cancer-Targeted Killer T Cells combines advantages of DPX platform and cancer antigen survivin, is lead candidate of IMV’s new class of immunotherapies that generates cancer-targeted T cells in vivo.

              Lead Product(s): Maveropepimut-S,Cyclophosphamide

              Therapeutic Area: Oncology Product Name: DPX-Survivac

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 28, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IMV

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IMV Inc. Presents Clinical Benefit of MVP-S in Combination with Pembrolizumab in Bladder Cancer at the AACR Annual Meeting

              Details:

              Combination of DPX-Survivac (maveropepimut-s) and pembrolizumab showed encouraging clinical activity in advanced, metastatic bladder cancer patients, particularly in patients who had received prior immune checkpoint inhibitor therapy.

              Lead Product(s): Maveropepimut-S,Pembrolizumab,Cyclophosphamide

              Therapeutic Area: Oncology Product Name: DPX-Survivac

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 08, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IMV

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IMV to Showcase its DPX® Delivery Technology in Two Presentations at the AACR Annual Meeting 2022

              Details:

              DPX-Survivac, a novel T cell immunotherapy that uses the DPX platform to elicit a coordinated anti-tumor immune response involving natural killer cells in both translational and preclinical studies.

              Lead Product(s): Maveropepimut-S,Cyclophosphamide

              Therapeutic Area: Oncology Product Name: DPX-Survivac

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 09, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY